IQVIA Reports Fourth-Quarter and Full-Year 2023 Results; Issues Full-Year 2024 Guidance
As of December 31, 2023, R&DS contracted backlog, including reimbursed expenses, was $29.7 billion, growing 9.2 percent year-over-year and 8.8 percent at constant currency.
- As of December 31, 2023, R&DS contracted backlog, including reimbursed expenses, was $29.7 billion, growing 9.2 percent year-over-year and 8.8 percent at constant currency.
- "The IQVIA team delivered solid 2023 results in a challenging macro environment," said Ari Bousbib, chairman and CEO of IQVIA.
- All financial guidance assumes foreign currency exchange rates as of February 12, 2024 remain in effect for the forecast period.
- IQVIA will host a conference call at 9:00 a.m. Eastern Time today to discuss its fourth-quarter and full-year 2023 results and 2024 guidance.